Three ASX stocks have enjoyed share price surges on Wednesday, after receiving positive reports on potentially lifesaving cancer treatments.
Therapeutic antibody development biotech, Patrys (ASX:PAB), surged 20 per cent after receiving favourable draft reports for its two recently completed toxicology studies testing of PAT-DX1 in animals.
The reports say there were no safety or tolerability issues associated with anti-cancer treatment PAT-DX1 in rats and non-human primate species that are likely to impede a human clinical trial.
This result is consistent with the favourable safety profile we’ve seen in previous toxicology studies for PAT-DX1.
For the latest health news, sign up here for free Stockhead daily newsletters
Two additional draft reports are expected by the end of July, which will provide further toxic characterisations of PAT-DX1.
Patrys expects to receive the final report towards the end of the year. It will be used to initiate a clinical trial of PAT-DX1.
CEO Dr James Campbell said that while Wednesday’s reports were still draft in nature, they typically would identify any major issues or areas of concern.
“So we do not expect the findings presented in the final report to differ materially,” he said.
“In the meantime, we believe that we will be able to restart manufacturing for the PAT-DX1 material for the clinical trial in Q3, 2023.”
MORE FROM STOCKHEAD: 4DMedical makes breakthrough | EBR achieves key catalyst | Orphan status boon for ASX stocks
Immutep’s Efti continues to progress
Immutep (ASX:IMM) climbed more than six per cent on Wednesday, after the company after announcing promising new clinical data from its triple combination therapy in INSIGHT-003 Trial.
The trial is studying the efficacy of Efti, Immutep’s lead drug, combined with standard-of-care anti-PD-1 therapy and doublet chemotherapy, in first line non-small cell lung cancer patients.
Results show that the triple combination is well tolerated, and continue to show promising initial signals of efficacy.
The therapy has achieved a 67 per cent response rate and 91 per cent disease control rate in the 21 patients enrolled, despite 81 per cent of patients having low or negative PD-L1 expression.
Apart from this trial, Efti is currently under evaluation for a variety of other solid tumours including neck squamous cell carcinoma (HNSCC) and metastatic breast cancer.
Visit Stockhead, where ASX small caps are big deals
The drug’s favourable safety profile enables various combinations, including with anti-PD-1 immunotherapy and/or chemotherapy.
Clarity to move to cohort 2
Clarity Pharmaceuticals’ (ASX:CU6) theranostic prostate cancer trial is now advancing to cohort 2 after the completion of cohort 1 dosing.
Cohort 1 was completed in six participants with metastatic castrate-resistant prostate cancer (mCRPC), who received therapy with 67Cu SAR-bisPSMA at the lowest dose level of 4GBq.
No dose-limiting toxicities were reported in cohort 1.
The Safety Review Committee has now recommended that the trial continues to cohort 2, where patients will be given a dose level of 8GBq.
At 2.30pm (AEST), CU6 was up more than 7 per cent for the day.
This content first appeared on stockhead.com.au
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox. Click here